	December 31,
	2018			2017
Building and leasehold improvements	$	77,771		$	81,444
Laboratory equipment		33,806			31,214
Computers, furniture, and other		31,354			27,800
Manufacturing equipment		21,339			20,695
Depreciable property, plant and equipment at cost		164,270			161,153
Less: accumulated depreciation		(120,507	)		(115,090	)
Depreciable property, plant and equipment, net		43,763			46,063
Construction-in-progress		5,088			1,400
Property, plant and equipment, net	$	48,851		$	47,463

Building and leasehold improvements include our manufacturing, research and development and administrative facilities and the related improvements to these facilities. Laboratory and manufacturing equipment include assets that support both our manufacturing and research and development efforts. Construction-in-progress includes assets being built to enhance our manufacturing and research and development efforts.

Depreciation and amortization expenses on property, plant and equipment for the years ended December 31, 2018, 2017, and 2016 was $8.8 million, $12.6 million, and $13.2 million, respectively.

In November 2017, Bayer announced that the Phase 3 Amikacin Inhale clinical program did not meet its primary endpoint or key secondary endpoints and, in December 2017, Bayer terminated our related collaboration agreement. Under this collaboration, we were responsible for the development, manufacturing and supply of our proprietary nebulizer device included in the Amikacin product and had acquired specific manufacturing equipment for this purpose. As a result of the termination of the program, in the three months ended December 31, 2017, we expensed program specific manufacturing equipment with an original cost of $23.4 million and a net book value of $15.1 million. We completed the disposal of this equipment in the first quarter of 2018. In addition, in the three months ended December 31, 2017, we incurred approximately $0.9 million of other program termination costs related to our manufacturing obligations.